American Society of Clinical Oncology Educational Book · 2022 · 25 citations · 49 references
MedicineOncologyPharmacotherapyBreast OncologyMetastasisMolecular OncologyCancer ImmunotherapyHer2-positive Breast CancerMetastatic Breast CancerMetastatic Cancer ManagementMetastatic Disease TreatmentSystemic Therapy For Breast CancerBreast Cancer Molecular SubtypesHer2 InhibitorsHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerSurvival RatesTreatment Intensity Selection
Patients with HER2-positive breast cancer account for approximately 15% to 20% of all breast cancers and represent one of the most aggressive breast cancer subtypes. Survival rates of patients with metastatic disease have improved dramatically and progressively. Many new agents have been developed, and long-term follow-up from trials of anti-HER2 agents has shown long-term responses. The availability of novel, highly active anti-HER2 treatments, together with the ongoing development of promising diagnostic tools, will offer the unprecedented opportunity to raise cure rates. Our ultimate goal is to tailor treatment intensity to disease and patient characteristics, hopefully increasing the fraction of cured patients while minimizing the risk for overtreatment. If conducted rationally and carefully, this plan has the potential to break a decades-long paradigm, leading to a new, precise era of treatment of HER2-positive breast cancer.
49
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 2K citations · Full text
Medicine, Oncology, Pharmacology +17
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +12
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
New England Journal of Medicine · 2022 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +17